Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway

Imatinib (IM), as first inhibitor of the oncogenic tyrosine kinase BCR-ABL, has been widely used to treat chronic myeloid leukemia (CML) for decades in clinic. However, resistance to IM usually occurs in CML patients. The bone marrow (BM), as the predominant microenvironment of CML, secretes an abun...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Pharmacol
Autors principals: Zhang, Xiaobo, Liu, Yicheng, Lu, Lu, Huang, Shaoliang, Ding, Youxiang, Zhang, Yi, Guo, Qinglong, Li, Zhiyu, Zhao, Li
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2017
Matèries:
Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5554535/
https://ncbi.nlm.nih.gov/pubmed/28848440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00526
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars